During Wednesday’s House subcommittee hearing on insulin price hikes, drug makers and benefits managers pointed fingers at each other for the last decade’s 300% price increase, frustrating congressional representatives.
from WebMD Health webmd
Popular Posts
-
Stubborn Fat problems The Issue at Hand Many people, no matter their age or gender, face common problem of stubborn fat. Even with stric... -
The project will initially cover about 60,000 patients in remote locations. from healthcareitnews
-
The 150-patient trial has problems of confounding, according to two experts, and is unable to answer definitively whether hydroxychloroquin...